In 2020, the FDA granted an expanded access program for the ERK inhibitor ulixertinib (BVD-523) for the treatment of cancer patients with abnormal MAPK pathways, including but not limited to those involving KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations [133]. Here, NRAS is linked to cancer.